Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 0 3 Month Treasury Bond ETF vs TransMedics Group Inc — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.52 (market cap $114.40B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 41.8× TransMedics Group Inc's market cap, and iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 0 3 Month Treasury Bond ETF for 50 Days and TransMedics Group Inc for 24 Days on average.
| SGOV | TMDX | |
|---|---|---|
Market Cap | $114.40B | $2.74B |
Volume | 18,879,081 | 949,331 |
Sector | Fixed Income | Health |
52-Week High | $100.72 | $150.42 |
52-Week Low | $100.28 | $61.99 |
Typical Hold Time | 50 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.515 with minimal daily movement, reflecting its stable nature. The technical picture is bearish according to moving averages, though oscillators are neutral. Recent corporate actions show consistent dividend payments. Market sentiment is influenced by broader bond market volatility and institutional positioning shifts.
The outlook for SGOV is tied to short-term Treasury yields and Federal Reserve policy. Opportunities include stability and income, but risks involve rising interest rates and institutional selling. Investors should weigh the ETF's defensive role against potential yield compression in a changing rate environment.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
